Helsinki-based healthtech company
Gosta Labs has closed a €7.5 million seed round to scale its AI operating
system for complex medical specialities. The round was led by Voima Ventures,
with participation from COR Group, the Aho family, and both existing and new
investors, including Reaktor and a group of notable angel investors. This
follows a €1.7 million pre-seed round in 2024 and brings the company’s total
funding to nearly €10 million.
Cancer care is becoming increasingly
complex. According to recent studies, by 2050, more than 35 million new cancer
cases are projected across over 100 cancer types. At the same time, clinicians
spend several hours per day on administrative tasks in fragmented systems with
largely unstructured clinical data, and multidisciplinary teams must make
rapid, high-stakes decisions across a growing range of personalized treatment
options.
Gosta Labs addresses these challenges
with an oncology-focused AI operating system that converts each patient visit
into high-quality structured data in real time. The system summarises and
visualises patient journeys, automates clinical documentation, and captures
structured clinical data relevant to patient care.
It also supports quality of
care by assessing key clinical parameters for each treatment pathway and
automatically linking decisions to international guidelines. This helps
oncologists deliver faster and more consistent care.
The first real-world results from the
Gosta AI Operating System were presented at the ESMO 2025 Congress. The
findings indicate that the system generates high-quality consultation notes in
real time, structured according to institutional standards. It also
automatically classifies Performance Status and CTCAE toxicity grades.
Oncologists were able to complete follow-up visit documentation in a median
time of under two minutes, reducing documentation workload and allowing more
time for direct patient care.
Founded in 2023 by Lauri Sippola and
Henri Viertolahti, the founders of Kaiku Health (acquired by Elekta in 2020),
Gosta Labs builds on a track record of developing and scaling regulated digital
health solutions globally. The team combines AI specialists with experienced
oncology and medtech leaders, including Chief Medical Officer Dr Lionel
Hadjadjeba and Chief Operating Officer Reetta Arokoski, both of whom have
extensive experience in scaling cancer care technologies internationally.
The new funding will be used to expand the reach of
its AI assistant to oncology teams globally and to further strengthen Gosta
Labs’ medical-device-grade product and AI foundation, enabling safer, more
personalised patient encounters with reduced administrative burden.